Adaptive Biotechnologies Corp (ADPT): EBITDA
-$41.12M
Year ended 2025-12-31
| Period ended | EBITDA | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$41.12M | n/m | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | -$145.11M | n/m | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | -$207.44M | n/c | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | -$179.27M | n/a | 2025-03-03, From 2022-01-01 |
EBITDA at similar companies
| Company | Year ended | EBITDA | Change YoY |
|---|---|---|---|
| Adaptive Biotechnologies Corp (ADPT) | 2025-12-31 | -$41.12M | n/m |
| Vericel Corp (VCEL) | 2025-12-31 | $22.59M | +125.4% |
| Iovance Biotherapeutics, Inc. (IOVA) | 2025-12-31 | -$367.42M | n/m |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $26.65M | n/m |
| Twist Bioscience Corp (TWST) | 2025-09-30 | -$111.41M | n/m |
| Immunocore Holdings plc (IMCR) | 2025-12-31 | -$42.25M | n/m |
| REGENXBIO Inc. (RGNX) | 2025-12-31 | -$145.58M | n/m |
| Ginkgo Bioworks Holdings, Inc. (DNA) | 2025-12-31 | -$256.29M | n/m |
| ADMA Biologics, Inc. (ADMA) | 2025-12-31 | $199.54M | +35.7% |
Compare ADPT, VCEL, IOVA, VXRT side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗